FcγRIIB specific antibodies and methods of use thereof
AssigneeMacroGenics, Inc.
InventorsScott Koenig, Maria Concetta Veri
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Claims40
A mouse monoclonal antibody produced by clone 3H7, having ATCC accession number PTA-4592 or an antigen binding fragment thereof.
An antibody including six CDRs from antibody produced by clone 3H7, having ATCC accession number PTA-4592 or an antigen binding fragment thereof, wherein the antibody is a chimeric or humanized version of the mouse monoclonal antibody, and wherein the antibody or fragment thereof comprises a variable domain that specifically binds the extracellular domain of FcγRIIB with greater affinity than said variable domain binds FcγRIIA.
A hybridoma cell line 3H7, having ATCC accession number PTA-4592.
A pharmaceutical composition comprising:
- (i.) a therapeutically effective amount of a first antibody including six CDRs from antibody produced by clone 3H7, having ATCC accession number PTA-4592, or an antigen binding fragment thereof, wherein the antibody is a chimeric or humanized version of the murine monoclonal antibody, and wherein the antibody or fragment thereof comprises a variable domain that specifically binds the extracellular domain of FcγRIIB with greater affinity than said variable domain binds FcγRIIA;
- (ii.) a second cytotoxic antibody that specifically binds a cancer antigen;
- and
- (iii.) a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising:
- (i.) a therapeutically effective amount of an antibody including six CDRs from antibody produced by clone 3H7, having ATCC accession number PTA-4592, or an antigen binding fragment thereof, wherein the antibody is a chimeric or humanized version of the murine monoclonal antibody, and wherein the antibody or fragment thereof comprises a variable domain that specifically binds the extracellular domain of FcγRIIB with greater affinity than said variable domain binds FcγRIIA;
- and
- (ii.) a pharmaceutically acceptable carrier.
An isolated antibody, or antigen binding fragment thereof, comprising a light chain variable region and a heavy chain variable region from the murine monoclonal antibody produced by clone 3H7, having ATCC accession number PTA-4592, wherein said antibody comprises a variable domain that specifically binds the extracellular domain of FcγRIIB with greater affinity than said variable domain binds FcγRIIA.
An isolated antibody, or antigen binding fragment thereof, comprising a light chain variable region from the murine monoclonal antibody produced by clone 3H7, having ATCC accession number PTA-4592, wherein said antibody comprises a variable domain that specifically binds the extracellular domain of FcγRIIB with greater affinity than said variable domain binds FcγRIIA.
An isolated antibody, or antigen binding fragment thereof, comprising a heavy chain variable region from the murine monoclonal antibody produced by clone 3H7, having ATCC accession number PTA-4592 wherein said antibody comprises a variable domain that specifically binds the extracellular domain of FcγRIIB with greater affinity than said variable domain binds FcγRIIA.
Dependencies are inferred from the claim text.